Psilocybin-assisted therapy for opioid use disorder
Part of Mental health clinical trials.
This study tests whether psilocybin (a psychedelic substance) combined with therapy can help people with opioid use disorder. Participants will receive the treatment in a controlled setting and be monitored for safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with moderate to severe opioid use disorder.
- You need a stable place to live.
- You must have a supportive friend or family member who can accompany you home after sessions.
- You must be willing to avoid caffeine for 12 hours, cannabis and alcohol for 24 hours, and all other drugs for 5 days before each treatment session.
- You need to attend all study visits and follow the study procedures.
- If you are able to become pregnant, you must use effective birth control and have negative pregnancy tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether psilocybin can help people who want to stop using opioids and are already in treatment. Eligible participants receive a single dose of psilocybin in a supervised setting and are followed to see if it reduces opioid use.
This trial tests whether psilocybin can help people recovering from opioid use disorder while living at a residential treatment center. If you are already taking buprenorphine/naloxone (Suboxone), methadone, or have received Sublocade, this study may be an option for you.
This study tests whether psilocybin, a psychedelic substance, can help change brain connections in people recovering from opioid use disorder. It involves brain scans and careful medical monitoring to explore new treatment options.
This study tests whether adding psilocybin (a psychedelic medicine) to buprenorphine (a medication for opioid use disorder) can help people stop using opioids and stay in recovery. It is for people who have already been on buprenorphine but are still using other opioids.
This Phase 1 study tests how adding psilocybin to a standard opioid treatment (buprenorphine-naloxone) affects recovery and symptoms in people with moderate-to-severe opioid use disorder. It may help researchers understand whether this combination is safe and beneficial alongside medication for opioid withdrawal and cravings.
This study tests whether a single dose of psilocybin (the active ingredient in magic mushrooms) can help people with opioid use disorder stay motivated in recovery. It uses brain scans to see how psilocybin affects brain areas linked to motivation.
Hear when a new Opioid Use Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.